Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 7/20 | 0.54 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800928 | 0.86 | CES2 (0.53) | MIFCYP26A1CES2MAOBKIT | |
| SCHEMBL6802315 | 0.86 | CES2 (0.53) | MIFCYP26A1CES2MAOBKIT | |
| SCHEMBL6800875 | 0.79 | ESR2 (0.38) | MIFCYP26A1MAOBESR1MAOA | |
| SCHEMBL6796152 | 0.78 | SMN1; SMN2 (0.53) | MIFCYP26A1CES2MAOBESR1 | |
| SCHEMBL6799095 | 0.76 | ACHE (0.53) | MAOBESR1 | |
| SCHEMBL6801825 | 0.76 | ESR2 (0.41) | ESR1 | |
| SCHEMBL6806282 | 0.76 | ESR2 (0.41) | ESR1 | |
| SCHEMBL6798898 | 0.74 | SMN1; SMN2 (0.43) | MIFCYP26A1CES2MAOBESR1 | |
| SCHEMBL6800175 | 0.74 | RELA (0.40) | MIFCES2MAOB | |
| SCHEMBL6796287 | 0.73 | MAOB (0.46) | MIFCYP26A1CES2MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | MERCK & CO., INC. | 2004-04-29 | — | — | US | claimed |
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | MERCK & CO., INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | ESRRA, ESRRB, FSHR | MIF 881/4885CYP26A1 353/4885CES2 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.